04Jan 2023
Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease

Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease

Hypoxia-inducible factor (HIF) stabilizers are approved to treat the anaemia of chronic kidney disease in different regions worldwide. However, regulatory agencies have raised concerns regarding cardiovascular safety. A puzzling observation is that the safety signal from HIF stabilizers concerning major adverse cardiovascular events (MACE) has ranged from potential protection to neutral to potential harm in diverse clinical trials, even for the same agent, without a clear explanation.

  • #family health

Like

Save

Share